AlphaStocks
7.4
Consider Buy

Bio-Rad Laboratories, Inc. (BIO)

As of Sep 20, 2026, Bio-Rad Laboratories, Inc. (BIO) scores 7.4/10 on AlphaStocks' five-model composite, #7 of 168 Health Care stocks.

Health Care / Life Sciences Tools & Services

S&P MidCap 400

$375.68

Above average across most dimensions. A solid candidate.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#7out of 168 in Health Care

Is BIO-RAD LABORATORIES, INC. a Good Investment in 2026?

BIO-RAD LABORATORIES, INC. (BIO) scores 7.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Greenblatt Magic Formula model rates BIO-RAD LABORATORIES, INC. as Strong (Earnings yield 15.3% · ROC 46%). The Buffett model is the least favorable, rating it Neutral. BIO-RAD LABORATORIES, INC. ranks #7 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E13.5ROE9.7Market Cap10B

Valuation

Trades at 13x earnings — near sector median of 30x.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Attractive

32% below fair value

Lynch

Attractive

PEG 0.3 · Fast Grower

Greenblatt

Strong

Earnings yield 15.3% · ROC 46%

Frequently Asked Questions

Is BIO-RAD LABORATORIES, INC. (BIO) a good investment?
As of Sep 20, 2026, Bio-Rad Laboratories, Inc. (BIO) scores 7.4/10 on AlphaStocks' five-model composite, #7 of 168 Health Care stocks. That score is above average across most investment dimensions. Trades at 13x earnings — near sector median of 30x.
What is BIO-RAD LABORATORIES, INC.'s Piotroski F-Score?
BIO-RAD LABORATORIES, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is BIO overvalued or undervalued?
A precise fair value estimate is not available for BIO. Trades at 13x earnings — near sector median of 30x.
How does BIO compare to other Health Care stocks?
BIO-RAD LABORATORIES, INC. ranks #7 out of 168 stocks in the Health Care sector, placing it in the top 4% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about BIO?
AlphaStocks evaluates BIO using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Attractive; Lynch: Attractive; Greenblatt Magic Formula: Strong. These models are combined into a single composite score of 7.4/10.

Similar Stocks

ILMNAZTAA

Compare BIO with

BIO vs ILMNAZTA vs BIOA vs BIO

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer